NR4A1 and neoplasm: Hormone therapy can be considered for patients with low-grade, low-volume disease who are not suitable for chemotherapy, dependent on knowledge of the hormone receptor status [estrogen receptor (ER) and progesterone receptor (PgR)] of the tumour at the time of treatment.